Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of FR104 in Healthy Subjects
NCT02800811Phase 1Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FR104 in rheumatoid arthritis (RA) and transplant rejection (4 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events at 4 months and Abnormalities in laboratory parameters at 4 months. Started Apr 2015; status: completed.
02
Drugs
FR104
03
Conditions
rheumatoid arthritis (RA)transplant rejection
Beyond the preview
Go deeper on NCT02800811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800811.